Featured Research

from universities, journals, and other organizations

New Devices Less Effective In Thwarting Brain Aneurysm Recurrence

Date:
February 21, 2008
Source:
University of Cincinnati
Summary:
A retrospective analysis of 100 patients suffering from a ruptured brain aneurysm has found that expensive new coiling devices are no more effective than bare platinum coils at preventing aneurysms from recurring.

Coil types used to treat aneurysms.
Credit: University of Cincinnati

A retrospective analysis of 100 patients suffering from a ruptured brain aneurysm has found that expensive new coiling devices are no more effective than bare platinum coils at preventing aneurysms from recurring.

A team of researchers from the Neuroscience Institute at the University of Cincinnati (UC) and University Hospital, led by Andrew Ringer, MD, evaluated the risk of intracranial aneurysm recurrence after endovascular treatment with each of three different kinds of coils.

Ringer, the study's principal investigator, is a neurosurgeon with the Mayfield Clinic and is director of endovascular neurosurgery and associate professor of neurosurgery at UC.

An intracranial aneurysm is a balloon-like bulge or blister on an artery in the brain. Aneurysms with thin necks, known as saccular aneurysms, are often treated with a clip. During a craniotomy, a procedure in which the skull is surgically opened, a neurosurgeon places the clip across the neck of the aneurysm, shutting off the aneurysm's blood supply.

Surgeons also can use a minimally invasive procedure to treat saccular aneurysms through coiling. A catheter is inserted into an artery in the groin and threaded up through the body to the brain, and a tiny coil is discharged directly into the aneurysm. The minimally invasive procedure enables the patient to avoid surgery and the risks associated with opening the skull.

In an important drawback, however, coils may occasionally compact within the aneurysm. When compaction occurs, blood flows back into the aneurysm, making repeated treatment necessary.

"Companies have tried to address the issue of recurrence after coiling by engineering coils using one of two different approaches," Ringer says. "One is coated with a polymer designed to promote tissue healing at the neck (opening) of the aneurysm, and one is coated with a gel that, when exposed to blood, is designed to expand inside the aneurysm to fill all the nooks and crannies.

"The purpose of our study was to assess the effectiveness of these new treatments," Ringer continues. "We found that neither of these newer--and more costly--coils performed any better than the bare platinum coils."

To determine whether the new strategies posed an improvement, Ringer and his research team analyzed the outcomes during a 3 -year period of 100 successively treated patients who had suffered ruptured aneurysms of medium size (five to 15 millimeters in diameter).

At the end of one year, the bare platinum coils were associated with the least number of repeated treatments. The percentage requiring repeated treatment was 6.4 percent in the platinum coils group, 11.5 percent in the expanding gel-coating group, and 20.9 percent in the polymer-coating group.

The results, Ringer says, "suggest the possibility that a factor, or factors, other than coil-surface coating may be responsible for reducing aneurysm recurrence."

The findings are being presented at the International Stroke Conference in New Orleans.

Other researchers involved in the study were Shah-Naz Khan, MD, a cerebrovascular fellow in the department of neurosurgery; Christopher Nichols, MD, an endovascular fellow in the department of neurology; and Todd Abruzzo, MD, assistant professor of neuroradiology. All are affiliated with the Neuroscience Institute.


Story Source:

The above story is based on materials provided by University of Cincinnati. Note: Materials may be edited for content and length.


Cite This Page:

University of Cincinnati. "New Devices Less Effective In Thwarting Brain Aneurysm Recurrence." ScienceDaily. ScienceDaily, 21 February 2008. <www.sciencedaily.com/releases/2008/02/080221162358.htm>.
University of Cincinnati. (2008, February 21). New Devices Less Effective In Thwarting Brain Aneurysm Recurrence. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/02/080221162358.htm
University of Cincinnati. "New Devices Less Effective In Thwarting Brain Aneurysm Recurrence." ScienceDaily. www.sciencedaily.com/releases/2008/02/080221162358.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins